HUMAN PERIPHERAL BLOOD LEUKOCYTES
Lymphoma, B-Cell
The First Affiliated Hospital of Soochow UniversityCell therapyPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
316 Active assets in the Lymphoma, B-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINDESINE Children's Cancer Group, China | Phase 4 | BBB |
cc-5013 Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Odronextamab University of Birmingham | Phase 3 | BBB |
METHOTREXATE Children's Cancer Group, China | Phase 4 | BBB |
Cytosin-Arabinosid Children's Cancer Group, China | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
HUMAN PERIPHERAL BLOOD LEUKOCYTES is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →